王永中, 方晓玲, 李雅娟, 张志文, 韩丽妹, 沙先谊. 紫杉醇Pluronic P105聚合物胶束的制备、表征与逆转肿瘤多药耐药性的体外研究J. 药学学报, 2008, 43(6): 640-646.
引用本文: 王永中, 方晓玲, 李雅娟, 张志文, 韩丽妹, 沙先谊. 紫杉醇Pluronic P105聚合物胶束的制备、表征与逆转肿瘤多药耐药性的体外研究J. 药学学报, 2008, 43(6): 640-646.
WANG Yong-zhong, FANG Xiao-ling, LI Ya-juan, ZHANG Zhi-wen, HAN Li-mei, SHA Xian-yi. Preparation, characterization of paclitaxel-loaded Pluronic P105 polymeric micelles and in vitro reversal of multidrug resistant tumorJ. Acta Pharmaceutica Sinica, 2008, 43(6): 640-646.
Citation: WANG Yong-zhong, FANG Xiao-ling, LI Ya-juan, ZHANG Zhi-wen, HAN Li-mei, SHA Xian-yi. Preparation, characterization of paclitaxel-loaded Pluronic P105 polymeric micelles and in vitro reversal of multidrug resistant tumorJ. Acta Pharmaceutica Sinica, 2008, 43(6): 640-646.

紫杉醇Pluronic P105聚合物胶束的制备、表征与逆转肿瘤多药耐药性的体外研究

Preparation, characterization of paclitaxel-loaded Pluronic P105 polymeric micelles and in vitro reversal of multidrug resistant tumor

  • 摘要: 药物递送系统是克服肿瘤多药耐药性(MDR)的一种新策略。本文以聚合物胶束系统和难溶性药物紫杉醇(PTX)为研究对象,旨在制备一种新型的PTX给药系统,既能增溶难溶性药物,又具有克服肿瘤MDR的能力。以Pluronic P105为载体,采用固体分散-水化法制备PTX聚合物胶束,并以星点设计-效应面优化法进行处方优化。对其粒径、体外释放等性质进行表征后,以人耐药卵巢癌细胞SKOV-3/PTX为细胞模型,体外评价PTX聚合物胶束的细胞摄取及其逆转肿瘤细胞耐药性的作用。结果显示,聚合物胶束制剂的载药量约为1.1%、药物浓度约为700 μg·mL-1、平均粒径约为24 nm。胶束制剂与普通制剂(Taxol)在6 h内的累积释放分别为45.4%和95.2%,前者具有较强的缓释作用;胶束制剂与Taxol对SKOV-3/PTX的IC50值分别为1.14和5.11 μg·mL-1,二者的耐药逆转指数(RRI)分别为9.65和2.15。胶束制剂可促进耐药细胞对P-糖蛋白(P-gp)底物(PTX或Rhodamine-123)的摄取。结果表明,Pluronic P105可有效增溶难溶性药物PTX,并形成具有较强缓释作用的纳米级聚合物胶束制剂,该制剂可显著提高PTX对人卵巢癌耐药细胞的细胞毒性,能逆转其耐药性。

     

    Abstract: Drug delivery system (DDS) is a novel approach to overcome multidrug resistance (MDR) in tumors nowadays. This work was designed to investigate a new micellar delivery system for in vitro reversal of resistant ovarian tumor cells, based on a nonionic triblock copolymer Pluronic P105 and paclitaxel (PTX). The PTX-loaded polymeric micelles (P105/PTX) were prepared by thin film-hydration methods. Based on the results of single factor experiments, the P105/PTX micelle formulation was optimized by employing the central composite design-response surface methodology. The physico-chemical properties of the P105/PTX micelles were characterized, including micelle size, drug loading coefficient, in vitro release behavior, etc. The cytotoxicity of the P105/PTX micelles was assessed against human ovarian tumor cell line, SKOV-3/PTX, by a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl (MTT) assay. In order to understand the possible mechanism of Pluronic effects in resistant tumor cells, cellular uptake study of micellar PTX or Rhodamine-123 (R-123) was also carried out. The results showed that the micelle size was about 24 nm with drug loading coefficient of 1.1% and PTX concentration of 700 μg·mL-1. The cumulative release amount of PTX from the P105/PTX micelles was only 45.4% in 6 h (P<0.05) and 79.6% in 24 h, whereas Taxol injection in 6 h released 95.2% PTX. The IC50 values of the P105/PTX micelles and Taxol injection against SKOV-3/PTX were 1.14 and 5.11 μg·mL-1, and resistance reversion index (RRI) was 9.65 and 2.15, respectively. The micellar PTX or R-123 exhibited a significant increase in cellular uptake in resistant SKOV-3/PTX cells compared with free PTX or R-123. These results indicated that PTX could effectively be solubilized by Pluronic P105 block copolymers via thin film-hydration process and formulation optimization, producing nano-scale polymeric micelles with sustained release property in vitro. The P105/PTX micelles were effectively able to reverse resistance to PTX in SKOV-3/PTX tumor cells compared with Taxol injection or free PTX solution, and the enhanced cytotoxicity in the resistant SKOV-3/PTX cell was related to the improved cellular uptake of PTX by Pluronic P105 copolymers.

     

/

返回文章
返回